Cardio Diagnostics Inc.

NasdaqCM: CDIO · Real-Time Price · USD
1.91
-0.08 (-4.02%)
At close: Aug 18, 2026, 3:59 PM

Cardio Diagnostics Inc. (CDIO) Stock Price, Analysis & Data

-4.02%
Bid1.41
Market Cap5.65M
Revenue (ttm)14.45K
Net Income (ttm)-6.47M
Beta2.22
EPS (ttm)-2.77
PE Ratio (ttm)n/a
Forward PE-7.64
P/B (ttm)0.76
P/S (ttm)391.18
Earnings DateNov 6, 2026
Ask2.32
Volume47,824
Avg. Volume (20D)67,703
Open2.00
Previous Close1.99
Day's Range1.77 - 2.01
52-Week Range0.97 - 7.91
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About CDIO

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platfo...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2022
Employees 15
Stock Exchange NasdaqCM
Ticker Symbol CDIO
Full Company Profile

Financial Performance

In 2025, Cardio Diagnostics's revenue was 14.82K, a decrease of -57.51% compared to the previous year's 34.89K. Earnings were -6.5M, a decrease of -22.49%.

Financial Statements

Earnings Surprise

Cardio Diagnostics has released their quarterly earnings on May 15, 2025:
  • Revenue of $2.68K misses estimates by $0, with 185.11% YoY growth.
  • EPS of -0.97 exceeds estimates by 0.83, with 83.83% YoY growth.
  • Cardio Diagnostics Inc. is scheduled to release its earnings on Nov 6, 2026, during market hours.
    Analysts project revenue of ... Upgrade